Recently, the vitamin D analogue calcipotriol was demonstrated to enhance PpIX accumulation in mice with chemical-induced cutaneous squamous cell carcinoma. 3 We evaluated the effect of topical calcipotriol (CAL) pretreatment on ablative fractional laser-assisted photodynamic therapy (AFL-PDT) outcomes in patients with actinic keratosis (AK). This prospective randomized clinical trial was registered in the ClinicalTrials.gov database (identifier: NCT02976727).
After excluding patients with abnormal serum vitamin D levels, calcium metabolic disorders, and allergy to drug components, 66 patients with facial AK were randomly assigned to receive either AFL-PDT after pretreatment with CAL (n ¼ 33) or AFL-PDT alone (n ¼ 33) by using a computer-generated program. Twice daily for 2 weeks, CAL-AFL-PDT patients received CAL (0.005% Daivonex, LEO Laboratories Ltd, Dublin, Ireland), and AFL-PDT patients received a topical placebo cream containing the same ingredients except calcipotriol. Afterwards, all patients underwent 1 session of AFL-PDT with the same protocol (ablation depth 300-550 m; coagulation level 1; treatment density 22%; single pulse). Methyl aminolevulinate application was followed by incubation (3 hours) and irradiation (dose 37 J/cm 2 ) with a red lighteemitting diode lamp. Curettage was not performed before PDT because of bleeding risk. Primary outcomes included complete response (CR) rate at 3 and 12 months after treatment and recurrence rate at 12 months. Secondary outcomes included cosmetic outcomes and treatment safety.
In total, 62 patients and 479 AK lesions (30 CAL-AFL-PDT patients with 245 lesions and 32 AFL-PDT patients with 234 lesions) were analyzed. There were no significant differences between groups regarding sex, age, Fitzpatrick score, or Olsen grade. The CAL-AFL-PDT group showed a higher rate of CR at 12 months (88.98% vs 79.91%, respectively, P ¼ .006, Table I ) 4 and a lower recurrence rate at 12 months (4.80% vs 10.10%, respectively, P ¼ .034) than the AFL-PDT group. The improvement of treatment efficacy was more pronounced for high-grade (Olsen grade III) lesions. Per patients, CR rates were slightly better in the CAL-AFL-PDT group at 3 months (CAL-AFL-PDT vs AFL-PDT, 90% vs 84.4%) and 12 months (CAL-AFL-PDT vs AFL-PDT, 83.3% vs 75%) than in the AFL-PDT group. We found no significant difference between the groups regarding cosmetic outcomes or treatment safety.
Our results indicate that CAL-AFL-PDT is more effective than AFL-PDT, particularly for thicklayered, moderate-to-severe AK lesions (Fig 1) . Topical calcipotriol promotes cell differentiation, apoptosis, and increases the efficacy of PDT by enhancing the activity of coproporphyrinogen oxidase in the heme biosynthetic pathway, promoting the accumulation of PpIX. 5 This study was limited by short follow-up, inclusion of patients from only 1 ethnic group, and lack of control for lifestyle factors, such as individual vitamin-D intake, nutritional factors, and physical activity. Therefore, these results require further verification. Nevertheless, we recommend topical calcipotriol administration before AFL-PDT especially for patients with thick-layered, moderateto-severe AK lesions. 
